| KOMISJA NADZORU FINANSOWEGO | ||||||||||||
| Raport bieżący nr | 2 | / | 2023 | |||||||||
| Data sporządzenia: | 2023-03-02 | |||||||||||
| Skrócona nazwa emitenta | ||||||||||||
| MILESTONE MEDICAL | ||||||||||||
| Temat | ||||||||||||
| The registration of CompuFlo Epidural System with the U.S. Government’s System for Award Management (SAM) | ||||||||||||
| Podstawa prawna | ||||||||||||
| Art. 17 ust. 1 MAR - informacje poufne. | ||||||||||||
| Treść raportu: | ||||||||||||
| The Board of Directors of Milestone Medical Inc. (WAR: MMD, “the Company", “the Issuer"), today announced that its CompuFlo® Epidural System has been granted registration with the U.S. Government’s System for Award Management (“SAM”). A SAM registration is required for entities to bid on contracts and conduct business with federal government agencies, including the Department of Defense, Department of Veterans Affairs, Indian Health Service and other government agencies. The Board of Directors of the Company is pleased to receive this SAM registration for the CompuFlo® Epidural System, which is required by all commercial entities to sell products within the U.S. government. Given the safety benefits and efficiencies associated with the instrument, the Board of Directors of the Company believes there is a market opportunity within agencies such as the Department of Defense and the Department of Veterans Affairs, where the CompuFlo® system can contribute to improved patient outcomes. This approval is an important step in the overall decision-making and payment process. In addition, The Board of Directors of the Company is actively pursuing U.S. Federal Supply Service (FSS) approval for the CompuFlo® Epidural Instrument which, if granted, would provide uniform pricing across government agencies. | ||||||||||||
| MESSAGE (ENGLISH VERSION) | |||
| MILESTONE MEDICAL INC | ||||||||||||||||
| (pełna nazwa emitenta) | ||||||||||||||||
| MILESTONE MEDICAL | ||||||||||||||||
| (skrócona nazwa emitenta) | (sektor wg. klasyfikacji GPW w W-wie) | |||||||||||||||
| NJ 07039 | . | |||||||||||||||
| (kod pocztowy) | (miejscowość) | |||||||||||||||
| South Orange Avenue Livingston | 220 | |||||||||||||||
| (ulica) | (numer) | |||||||||||||||
| +11 973 535 2717 | +11 973 535 2829 | |||||||||||||||
| (telefon) | (fax) | |||||||||||||||
| (e-mail) | (www) | |||||||||||||||
| 27-5484393 | ||||||||||||||||
| (NIP) | (REGON) | |||||||||||||||
| PODPISY OSÓB REPREZENTUJĄCYCH SPÓŁKĘ | |||||
| Data | Imię i Nazwisko | Stanowisko/Funkcja | Podpis | ||
| 2023-03-02 | Keisha Harcum | Controller | Keisha Harcum | ||
